Abstract:After experiencing the failures of first and second generations of HIV vaccines,the RV144 trial in Thailand,combining pox virus and gp120 vaccines,shows a 31％ protection for the first time in human study.The main scientific challenge to the vaccine of a Lentivirus where HIV belongs,is the lack of protective immunity in natural infection.Therefore,novel approaches have to be developed to overcome this bottleneck in evolution.Research progresses are made in the following areas:Finding the extremely broad neutralizing antibody (bNAb) and studying their maturation mechanism from the elite controller in HIV infected people;rational design of novel HIV immunogen to trigger germline B cells activation of the bNAb;stabilizing the HIV envelope trimers and enhancing their ability to induce bNAb;using replication competent vector to strengthen the immunogenicity and durability.Only four phase Ⅱb/Ⅲ clinical trials have been conducted in the first 30 years of HIV vaccine research.More than five phase Ⅱb/Ⅲ HIV vaccine clinical trials have been planned for the next 5 years.To repeat the RV144 trial in African,NIH started the P5 project of ALVAC/gpl20 vaccine started in late 2016.The Harvard and Johnson's collaborative Ad 26/GP140 vaccine trial will be initiated in 2017/2018.To compare the replicating (rTV) and non-replication (ALVAC) pox virus vector,China CDC and NIH will conduct a joint trial of combining their DNA/rTV with gP145 vaccines in China.The two funded CHAVI-ID groups led by Duke University and the Scripps Research Institute as well as the Vaccine Research Center of NIH will push their HIV env trimer vaccine to Phase Ⅱb trials.With the past successes in the first two lentivirus (EIAV and FIV) vaccines and the 31％ human protection of RV144,HIV vaccine research will definitely contribute to the course of Ending AIDS Epidemic by 2030.

[Advances in the Immunogenic Design of HIV-1 Vaccine].

Scientific Challenge and Advances of the HIV Vaccine Research

Progress in HIV-1 Vaccine Development.

HIV-1 Antibodies from Infection and Vaccination: Insights for Guiding Vaccine Design

Design and Immunogenicity Assessment of HIV-1 Virus-Like Particles As a Candidate Vaccine.

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

Correlates of Protection, Antigen Delivery and Molecular Epidemiology: Basics for Designing an Hiv Vaccine

Receptor Binding Domain Based HIV Vaccines

HIV Vaccine Development at a Crossroads: New B and T Cell Approaches

Broadly neutralizing antibodies against human immunodeficiency virus type 1(HIV-1) and rational design of HIV-1 vaccines

Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Antibody-based Candidate Therapeutics Against HIV-1: Implications for Virus Eradication and Vaccine Design

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection

HIV/AIDS vaccine development: are we walking out from the dark?

Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1

An Immunogen Containing Four Tandem 10E8 Epitope Repeats with Exposed Key Residues Induces Antibodies That Neutralize HIV-1 and Activates an ADCC Reporter Gene.

Epitope-vaccine strategy against HIV-1: today and tomorrow.

[Progress in HIV-1 Env Trimer Design].

HIV Vaccines and Cure